<html xmlns:v="urn:schemas-microsoft-com:vml"
xmlns:o="urn:schemas-microsoft-com:office:office"
xmlns:w="urn:schemas-microsoft-com:office:word"
xmlns:st1="urn:schemas-microsoft-com:office:smarttags"
xmlns="http://www.w3.org/TR/REC-html40">

<head>
<meta http-equiv=Content-Type content="text/html; charset=windows-1252">
<meta name=ProgId content=Word.Document>
<meta name=Generator content="Microsoft Word 10">
<meta name=Originator content="Microsoft Word 10">
<link rel=File-List
href="BIOTECH_ABSTRACTS_AND_BIOS_COMBINED_files/filelist.xml">
<link rel=Edit-Time-Data
href="BIOTECH_ABSTRACTS_AND_BIOS_COMBINED_files/editdata.mso">
<link rel=OLE-Object-Data
href="BIOTECH_ABSTRACTS_AND_BIOS_COMBINED_files/oledata.mso">
<!--[if !mso]>
<style>
v\:* {behavior:url(#default#VML);}
o\:* {behavior:url(#default#VML);}
w\:* {behavior:url(#default#VML);}
.shape {behavior:url(#default#VML);}
</style>
<![endif]-->
<title>8:30 – 9:30</title>
<o:SmartTagType namespaceuri="urn:schemas-microsoft-com:office:smarttags"
 name="time"/>
<o:SmartTagType namespaceuri="urn:schemas-microsoft-com:office:smarttags"
 name="country-region"/>
<o:SmartTagType namespaceuri="urn:schemas-microsoft-com:office:smarttags"
 name="place"/>
<o:SmartTagType namespaceuri="urn:schemas-microsoft-com:office:smarttags"
 name="address"/>
<o:SmartTagType namespaceuri="urn:schemas-microsoft-com:office:smarttags"
 name="PlaceType"/>
<o:SmartTagType namespaceuri="urn:schemas-microsoft-com:office:smarttags"
 name="State"/>
<o:SmartTagType namespaceuri="urn:schemas-microsoft-com:office:smarttags"
 name="City"/>
<o:SmartTagType namespaceuri="urn:schemas-microsoft-com:office:smarttags"
 name="PlaceName"/>
<o:SmartTagType namespaceuri="urn:schemas-microsoft-com:office:smarttags"
 name="PostalCode"/>
<o:SmartTagType namespaceuri="urn:schemas-microsoft-com:office:smarttags"
 name="Street"/>
<!--[if gte mso 9]><xml>
 <o:DocumentProperties>
  <o:Author>siokmf</o:Author>
  <o:LastAuthor>Kiran Dambala</o:LastAuthor>
  <o:Revision>3</o:Revision>
  <o:TotalTime>16</o:TotalTime>
  <o:Created>2005-07-21T04:15:00Z</o:Created>
  <o:LastSaved>2005-07-21T04:15:00Z</o:LastSaved>
  <o:Pages>1</o:Pages>
  <o:Words>3381</o:Words>
  <o:Characters>19278</o:Characters>
  <o:Company>Lockheed Martin</o:Company>
  <o:Lines>160</o:Lines>
  <o:Paragraphs>45</o:Paragraphs>
  <o:CharactersWithSpaces>22614</o:CharactersWithSpaces>
  <o:Version>10.2625</o:Version>
 </o:DocumentProperties>
</xml><![endif]--><!--[if gte mso 9]><xml>
 <w:WordDocument>
  <w:PunctuationKerning/>
  <w:Compatibility>
   <w:BreakWrappedTables/>
   <w:SnapToGridInCell/>
   <w:WrapTextWithPunct/>
   <w:UseAsianBreakRules/>
  </w:Compatibility>
  <w:BrowserLevel>MicrosoftInternetExplorer4</w:BrowserLevel>
 </w:WordDocument>
</xml><![endif]--><!--[if !mso]><object
 classid="clsid:38481807-CA0E-42D2-BF39-B33AF135CC4D" id=ieooui></object>
<style>
st1\:*{behavior:url(#ieooui) }
</style>
<![endif]-->
<style>
<!--
 /* Font Definitions */
 @font-face
	{font-family:Times;
	panose-1:2 2 6 3 5 4 5 2 3 4;
	mso-font-charset:0;
	mso-generic-font-family:roman;
	mso-font-pitch:variable;
	mso-font-signature:536902279 -2147483648 8 0 511 0;}
 /* Style Definitions */
 p.MsoNormal, li.MsoNormal, div.MsoNormal
	{mso-style-parent:"";
	margin:0in;
	margin-bottom:.0001pt;
	mso-pagination:widow-orphan;
	font-size:12.0pt;
	font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";}
h1
	{mso-style-next:Normal;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:center;
	mso-pagination:widow-orphan;
	page-break-after:avoid;
	mso-outline-level:1;
	font-size:12.0pt;
	font-family:"Times New Roman";
	mso-font-kerning:0pt;}
h3
	{mso-style-next:Normal;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.25in;
	margin-bottom:.0001pt;
	text-align:center;
	mso-pagination:widow-orphan;
	page-break-after:avoid;
	mso-outline-level:3;
	font-size:12.0pt;
	font-family:"Times New Roman";}
p.MsoHeader, li.MsoHeader, div.MsoHeader
	{margin:0in;
	margin-bottom:.0001pt;
	mso-pagination:widow-orphan;
	tab-stops:center 3.0in right 6.0in;
	font-size:12.0pt;
	font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";}
p.MsoFooter, li.MsoFooter, div.MsoFooter
	{margin:0in;
	margin-bottom:.0001pt;
	mso-pagination:widow-orphan;
	tab-stops:center 3.0in right 6.0in;
	font-size:12.0pt;
	font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";}
p.MsoTitle, li.MsoTitle, div.MsoTitle
	{margin:0in;
	margin-bottom:.0001pt;
	text-align:center;
	mso-pagination:widow-orphan;
	font-size:12.0pt;
	font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";
	font-weight:bold;
	mso-bidi-font-weight:normal;}
p.MsoBodyText, li.MsoBodyText, div.MsoBodyText
	{margin:0in;
	margin-bottom:.0001pt;
	mso-pagination:widow-orphan;
	font-size:8.0pt;
	mso-bidi-font-size:10.0pt;
	font-family:Times;
	mso-fareast-font-family:Times;
	mso-bidi-font-family:"Times New Roman";}
p.MsoBodyText2, li.MsoBodyText2, div.MsoBodyText2
	{margin:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	mso-pagination:widow-orphan;
	font-size:12.0pt;
	font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";}
a:link, span.MsoHyperlink
	{color:blue;
	text-decoration:underline;
	text-underline:single;}
a:visited, span.MsoHyperlinkFollowed
	{color:purple;
	text-decoration:underline;
	text-underline:single;}
address
	{mso-style-parent:"z-Top of Form";
	margin:0in;
	margin-bottom:.0001pt;
	mso-pagination:widow-orphan;
	font-size:12.0pt;
	mso-bidi-font-size:10.0pt;
	font-family:"Times New Roman";
	font-style:normal;}
 /* Page Definitions */
 @page
	{mso-footnote-separator:url("BIOTECH_ABSTRACTS_AND_BIOS_COMBINED_files/header.htm") fs;
	mso-footnote-continuation-separator:url("BIOTECH_ABSTRACTS_AND_BIOS_COMBINED_files/header.htm") fcs;
	mso-endnote-separator:url("BIOTECH_ABSTRACTS_AND_BIOS_COMBINED_files/header.htm") es;
	mso-endnote-continuation-separator:url("BIOTECH_ABSTRACTS_AND_BIOS_COMBINED_files/header.htm") ecs;}
@page Section1
	{size:8.5in 11.0in;
	margin:1.0in 1.25in 1.0in 1.25in;
	mso-header-margin:.5in;
	mso-footer-margin:.5in;
	mso-header:url("BIOTECH_ABSTRACTS_AND_BIOS_COMBINED_files/header.htm") h1;
	mso-paper-source:0;}
div.Section1
	{page:Section1;}
 /* List Definitions */
 @list l0
	{mso-list-id:1334062636;
	mso-list-type:hybrid;
	mso-list-template-ids:197671824 -843915210 67698713 67698715 67698703 67698713 67698715 67698703 67698713 67698715;}
@list l0:level1
	{mso-level-tab-stop:.75in;
	mso-level-number-position:left;
	margin-left:.75in;
	text-indent:-.5in;}
@list l0:level2
	{mso-level-number-format:alpha-lower;
	mso-level-tab-stop:1.0in;
	mso-level-number-position:left;
	text-indent:-.25in;}
ol
	{margin-bottom:0in;}
ul
	{margin-bottom:0in;}
-->
</style>
<!--[if gte mso 10]>
<style>
 /* Style Definitions */
 table.MsoNormalTable
	{mso-style-name:"Table Normal";
	mso-tstyle-rowband-size:0;
	mso-tstyle-colband-size:0;
	mso-style-noshow:yes;
	mso-style-parent:"";
	mso-padding-alt:0in 5.4pt 0in 5.4pt;
	mso-para-margin:0in;
	mso-para-margin-bottom:.0001pt;
	mso-pagination:widow-orphan;
	font-size:10.0pt;
	font-family:"Times New Roman";}
</style>
<![endif]-->
</head>

<body lang=EN-US link=blue vlink=purple style='tab-interval:.5in'>

<div class=Section1>

<p class=MsoTitle><o:p>&nbsp;</o:p></p>

<h1 align=left style='text-align:left'><st1:time Minute="30" Hour="8">8:30 –
 9:30</st1:time></h1>

<h1><span style='mso-bidi-font-weight:normal'>Nano and Microcrystalline Silicon
as a Diverse Biomaterial Platform<o:p></o:p></span></h1>

<p class=MsoNormal align=center style='text-align:center'><span
style='mso-spacerun:yes'> </span>Jeffery L. Coffer, Ph.D.</p>

<p class=MsoNormal align=center style='text-align:center'>Professor and Chair</p>

<p class=MsoNormal align=center style='text-align:center'>Department of
Chemistry</p>

<p class=MsoNormal align=center style='text-align:center'><st1:place><st1:PlaceName>Texas</st1:PlaceName>
 <st1:PlaceName>Christian</st1:PlaceName> <st1:PlaceName>University</st1:PlaceName></st1:place></p>

<p class=MsoNormal align=center style='text-align:center'><st1:place><st1:City>Fort
  Worth</st1:City>, <st1:State>TX</st1:State><span style='mso-spacerun:yes'> 
 </span><st1:PostalCode>76129</st1:PostalCode></st1:place></p>

<address><span style='mso-bidi-font-size:12.0pt'><o:p>&nbsp;</o:p></span></address>

<p class=MsoBodyText style='text-align:justify'><b style='mso-bidi-font-weight:
normal'><u><span style='font-size:12.0pt;mso-bidi-font-size:10.0pt'>ABSTRACT</span></u></b><span
style='font-size:12.0pt;mso-bidi-font-size:10.0pt'>:<span
style='mso-spacerun:yes'>  </span>With a long–term interest in multifunctional
semiconducting nanostructures relevant to biomaterials, we seek to successfully
construct rapidly-adaptive platforms based on electrically-responsive,
mechanically-robust tunable artificial nanostructures that are not only
biocompatible, but furthermore bioactive, and whose activity can be altered not
only by physical dimension and chemical composition but external stimuli as
well. Recent focus has entailed studies of the bottom up synthesis of elemental
silicon dots and wires, top down fabrication of spongy porous Si structures,
and fundamental studies of surface modification and diffusion from these
matrices. Incorporation of the proper inorganic component to the nanostructures
brings mechanical strength and semiconductive character; Porosity allows for the
release of therapeutic release of useful substances from the material, as well
as proper vasculature &amp; neural in-growth to the scaffold; in some cases,
composite formulation with biopolymers brings tunability to the structure in
terms of biodegradability. This presentation will provide examples from the
above categories, with discussion of material fabrication requirements,
structural characterization, and bio-relevant properties.<o:p></o:p></span></p>

<p class=MsoBodyText2><o:p>&nbsp;</o:p></p>

<p class=MsoNormal style='text-align:justify'><b style='mso-bidi-font-weight:
normal'><u>BIOGRAPHY</u></b>:<span style='mso-spacerun:yes'>  </span><span
style='color:black'>Jeff Coffer, a native of South Carolina, earned his B.S.
degree in Chemistry from Wofford College (SC) in 1982, a Ph.D. in inorganic
chemistry from the University of Wisconsin in 1987, and from 1987-1989 Dr.
Coffer was a postdoctoral fellow at the School of Chemical Sciences and
Materials Research Laboratory of the University of Illinois, Urbana-Champaign
.<span style='mso-spacerun:yes'>  </span>He joined the faculty of </span><st1:place><st1:PlaceName><span
  style='color:black'>Texas</span></st1:PlaceName><span style='color:black'> </span><st1:PlaceName><span
  style='color:black'>Christian</span></st1:PlaceName><span style='color:black'>
 </span><st1:PlaceName><span style='color:black'>University</span></st1:PlaceName></st1:place><span
style='color:black'> in 1990 and currently holds the rank of Professor of
Chemistry and Chair of the Department. Dr. Coffer also maintains adjunct
appointments in Materials Science at the </span><st1:place><st1:PlaceType><span
  style='color:black'>University</span></st1:PlaceType><span style='color:black'>
 of </span><st1:PlaceName><span style='color:black'>North Texas</span></st1:PlaceName></st1:place><span
style='color:black'> and the Institute for Cancer Research at the University of
North Texas Health Science Center, and formerly was a Visiting Scientist at the
</span><st1:place><st1:PlaceName><span style='color:black'>Kilby</span></st1:PlaceName><span
 style='color:black'> </span><st1:PlaceName><span style='color:black'>Research</span></st1:PlaceName><span
 style='color:black'> </span><st1:PlaceType><span style='color:black'>Center</span></st1:PlaceType></st1:place><span
style='color:black'> at Texas Instruments, </span><st1:place><st1:City><span
  style='color:black'>Dallas</span></st1:City><span style='color:black'>, </span><st1:State><span
  style='color:black'>Texas</span></st1:State></st1:place><span
style='color:black'>. His current research interests include the development of
new semiconducting nanomaterials relevant to both biomaterial<span
style='mso-spacerun:yes'>  </span>applications as well as optoelectronics.<span
style='mso-spacerun:yes'>  </span>He has published more than 85 refereed papers.</span></p>

<p class=MsoBodyText2><o:p>&nbsp;</o:p></p>

<p class=MsoNormal><o:p>&nbsp;</o:p></p>

<p class=MsoNormal align=center style='text-align:center'>**********************************************************************</p>

<h1 align=left style='text-align:left'><st1:time Minute="45" Hour="9">9:45 –
 10:45</st1:time></h1>

<h1><span style='mso-bidi-font-size:11.0pt;mso-bidi-font-weight:normal'>Engineering
of Ocular Drug Delivery Systems</span><span style='mso-bidi-font-weight:normal'><o:p></o:p></span></h1>

<p class=MsoNormal align=center style='text-align:center;mso-layout-grid-align:
none;text-autospace:none'><span style='mso-bidi-font-size:11.0pt'>Alan Weiner,
Ph.D.<o:p></o:p></span></p>

<p class=MsoNormal align=center style='text-align:center;mso-layout-grid-align:
none;text-autospace:none'><span style='mso-bidi-font-size:11.0pt'>Senior
Director, Development<o:p></o:p></span></p>

<p class=MsoNormal align=center style='text-align:center;mso-layout-grid-align:
none;text-autospace:none'><span style='mso-bidi-font-size:11.0pt'>Alcon
Research Ltd.<o:p></o:p></span></p>

<p class=MsoNormal align=center style='text-align:center;mso-layout-grid-align:
none;text-autospace:none'><st1:place><st1:City><span style='mso-bidi-font-size:
  11.0pt'>Fort Worth</span></st1:City><span style='mso-bidi-font-size:11.0pt'>,
 </span><st1:State><span style='mso-bidi-font-size:11.0pt'>Texas</span></st1:State><span
 style='mso-bidi-font-size:11.0pt'><span style='mso-spacerun:yes'>  </span></span><st1:PostalCode>76134-2099</st1:PostalCode></st1:place><span
style='mso-bidi-font-size:11.0pt'><o:p></o:p></span></p>

<p class=MsoNormal align=center style='margin-left:.25in;text-align:center'><o:p>&nbsp;</o:p></p>

<p class=MsoNormal style='text-align:justify'><b style='mso-bidi-font-weight:
normal'><u><span style='mso-bidi-font-size:11.0pt'>ABSTRACT</span></u></b><span
style='mso-bidi-font-size:11.0pt'>:<span style='mso-spacerun:yes'>  </span>There
are a wide range of biomaterials that have been either commercialized or
studied in the human eye.<span style='mso-spacerun:yes'>  </span>Approved
devices for use or implantation in the eye include contact lenses, intraocular
lenses, scleral buckles and balloons, artificial prosthetics (i.e., whole or
partial eye), punctal plugs, intravitreal slow release devices, glaucoma
filtration shunts, scleral expanders, vitreous tamponades, viscoelastics,
ocular surface inserts and artificial cornea.<span style='mso-spacerun:yes'> 
</span>This broad historical experience with surgical procedures for correcting
disorders and diseases of the eye has fostered an extensive understanding of
biomaterial compatibility with ocular tissues.<span style='mso-spacerun:yes'> 
</span>An extension of this knowledge is increasingly being bridged with the
need to deliver therapeutic agents from such devices.<span
style='mso-spacerun:yes'>  </span></span>For ocular therapy, potential
administration routes for drug delivery devices include topical, punctal,
subconjunctival, intravitreal, juxtascleral, intrascleral and subretinal as
well as parenteral administration, including oral.<span
style='mso-spacerun:yes'>  </span>Engineering of these devices is dependant on
a) whether the need is for therapy of acute or chronic disease, b) the size or
volume allowable within the chosen tissue and c) drug diffusion or distribution
from the particular implant site to the site of action.<span
style='mso-spacerun:yes'>  </span>Most challenging have been systems which
treat chronic diseases such as macular degeneration and neovascularization,
glaucoma, diabetic retinopathies, edema, and dry eye syndromes.<span
style='mso-spacerun:yes'>  </span>For these applications ocular system designs
typically involve either reservoir or matrix drug delivery mechanisms.<span
style='mso-spacerun:yes'>   </span>Reservoir systems generally provide more precise
rate control but often involve more complex surgical procedures for
implantation and removal.<span style='mso-spacerun:yes'>  </span>Erodible
matrix systems are usually dependant on more than one factor for rate control
(i.e. drug dissolution, drug release and polymer/excipient erosion) and may be
subject to restrictions of total drug loading.<span style='mso-spacerun:yes'> 
</span><span style='mso-bidi-font-size:11.0pt'>This presentation will examine
the range of biomaterial systems, either marketed, in clinical trials, or in
preclinical experimental models, that facilitate drug delivery to ocular
tissues.<span style='mso-spacerun:yes'>  </span>The physiological challenges to
device retention and maintenance of effective drug delivery will be reviewed.<o:p></o:p></span></p>

<p class=MsoBodyText2><o:p>&nbsp;</o:p></p>

<p class=MsoNormal style='text-align:justify'><b style='mso-bidi-font-weight:
normal'><u>BIOGRAPHY</u></b>:<span style='mso-spacerun:yes'>  </span><span
style='color:black;layout-grid-mode:line'>Dr. Alan Weiner is currently Senior
Director, Development at Alcon Research, Ltd. and is in charge of the groups
that develop the research formulations and dosage forms for Alcon’s
pharmaceutical and surgical therapeutic products, including drug delivery
systems.<span style='mso-spacerun:yes'>  </span>He has previously served there
as Senior Director Glaucoma Clinical Science, and as</span><span
style='layout-grid-mode:line'> Director, Scientific Affairs and Market Development,
Glaucoma<span style='color:black'>.<span style='mso-spacerun:yes'>  </span></span>Before
joining Alcon 10 years ago, Dr. Weiner was a founding scientist of two drug
delivery based companies - Escalon Ophthalmics and The Liposome Company, now
part of Elan Pharmaceuticals.<span style='mso-spacerun:yes'>  </span>Dr. Weiner
received his <span style='color:black'>Ph.D. in Biochemistry from </span></span><st1:place><st1:PlaceName><span
  style='color:black;layout-grid-mode:line'>Rutgers</span></st1:PlaceName><span
 style='color:black;layout-grid-mode:line'> </span><st1:PlaceType><span
  style='color:black;layout-grid-mode:line'>University</span></st1:PlaceType></st1:place><span
style='color:black;layout-grid-mode:line'> and maintains an appointment as </span><span
style='layout-grid-mode:line'>Adjunct Professor in the Molecular Biology and
Immunology department at the University of North Texas Health Science Center.
Dr. Weiner is an inventor on over 30 </span><st1:country-region><st1:place><span
  style='layout-grid-mode:line'>US</span></st1:place></st1:country-region><span
style='layout-grid-mode:line'> patents, and has authored numerous publications
and book chapters involving drug delivery systems over the last 25 years.<o:p></o:p></span></p>

<p class=MsoBodyText2><o:p>&nbsp;</o:p></p>

<p class=MsoNormal><o:p>&nbsp;</o:p></p>

<p class=MsoNormal align=center style='text-align:center'>**********************************************************************</p>

<h1 align=left style='text-align:left'><st1:time Minute="0" Hour="11">11:00 –
 12:00</st1:time></h1>

<p class=MsoNormal align=center style='text-align:center'><b>Confocal Total
Internal Reflection Microscopy: <o:p></o:p></b></p>

<p class=MsoNormal align=center style='text-align:center'><b>A Novel Technique
of Investigating Single Molecules in Tissue<o:p></o:p></b></p>

<p class=MsoNormal align=center style='text-align:center'>Julian Borejdo,<sup>1</sup>
J. Talent,<sup>1</sup> <st1:place>I.</st1:place> Akopova,<sup>1</sup> and T.P.
Burghardt<sup>2<o:p></o:p></sup></p>

<p class=MsoNormal align=center style='text-align:center'><sup>1</sup>Dept of
Molecular Biology &amp; Immunology</p>

<p class=MsoNormal align=center style='text-align:center'><st1:place><st1:City>University
  of North</st1:City> <st1:State>Texas</st1:State></st1:place> HSC</p>

<p class=MsoNormal align=center style='text-align:center'><st1:place><st1:City>Fort
  Worth</st1:City>, <st1:State>TX</st1:State> <st1:PostalCode>76107</st1:PostalCode></st1:place>
</p>

<p class=MsoNormal align=center style='text-align:center'><o:p>&nbsp;</o:p></p>

<p class=MsoNormal align=center style='text-align:center'><sup>2</sup>Dept of
Biochemistry</p>

<p class=MsoNormal align=center style='text-align:center'>Mayo Clinic</p>

<p class=MsoNormal align=center style='text-align:center'><st1:place><st1:City>Rochester</st1:City>,
 <st1:State>MN</st1:State> <st1:PostalCode>55905</st1:PostalCode></st1:place></p>

<p class=MsoNormal align=center style='text-align:center'><o:p>&nbsp;</o:p></p>

<p class=MsoNormal style='text-align:justify'><b style='mso-bidi-font-weight:
normal'><u>ABSTRACT</u></b>:<span style='mso-spacerun:yes'>  </span>Proteins in
cells are present in micromolar concentrations. Observing kinetics of single
protein molecules <i style='mso-bidi-font-style:normal'><u>in vivo</u></i>
requires therefore that signal be collected from attoliter (10<sup>-18</sup>L)
volume. Confocal Total Internal Reflection provides a way to obtain such data
with high Signal-to-Noise. In this method, the observational volume is made
shallow by illuminating sample with evanescent field produced by total internal
reflection of the incident laser beam. A confocal aperture inserted in the
image plane of the objective guarantees the small lateral dimensions of the
observational volume. It is shown, by measuring diffusion of fluorescent
microspheres, that the evanescent field is ~110 nm deep. 3.5 <span lang=EL
style='mso-ansi-language:EL'>&#956;</span>m confocal aperture gives lateral
dimensions of 120 nm x 120 nm, i.e. the observational volume of 1.5 attoL. The
technique was applied to measuring kinetics of single myosin molecule in muscle
fiber. Association-dissociation of myosin head was probed with rhodamine
attached at Cys707 of the heavy chain of myosin, and the power stroke was
probed with rhodamine attached to Cys73 of genetically engineered regulatory
light chain exchanged into muscle. Fluorescence measured from the myofibrillar
A-band was contributed by ~1-20 rhodamine molecules. Fluorescence decayed in a
series of discrete steps, corresponding to bleaching of individual molecules of
rhodamine. Signal was compared from myofibril in rigor and during isometric
contraction. Shortening of myofibrils was prevented by light cross-linking with
1-ethyl-3-[3-dimethylamino)-propyl]-carbodiimide. Cross-bridge labeled at the
head rotated at the rate approximately equal to the ATPase. Cross-bridge
labeled at the lever arm rotated slower than the ATPase rate. These results
suggest that during contraction of muscle fibers, hydrolysis of one ATP
molecule does not always lead to a power stroke. </p>

<p class=MsoNormal><o:p>&nbsp;</o:p></p>

<p class=MsoBodyText style='text-align:justify'><b style='mso-bidi-font-weight:
normal'><u><span style='font-size:12.0pt;font-family:"Times New Roman"'>BIOGRAPHY</span></u></b><span
style='font-size:12.0pt;font-family:"Times New Roman"'>:<span
style='mso-spacerun:yes'>  </span>Julian Borejdo earned the B.A. and Ph.D.
degrees in Mathematics and Physics from </span><st1:place><st1:PlaceName><span
  style='font-size:12.0pt;font-family:"Times New Roman"'>Macquarie</span></st1:PlaceName><span
 style='font-size:12.0pt;font-family:"Times New Roman"'> </span><st1:PlaceType><span
  style='font-size:12.0pt;font-family:"Times New Roman"'>University</span></st1:PlaceType></st1:place><span
style='font-size:12.0pt;font-family:"Times New Roman"'> in </span><st1:country-region><st1:place><span
  style='font-size:12.0pt;font-family:"Times New Roman"'>Australia</span></st1:place></st1:country-region><span
style='font-size:12.0pt;font-family:"Times New Roman"'>, in 1971 and 1974,
respectively.<span style='mso-spacerun:yes'>  </span>Afterwards, he was a
Katzir-Katchalsky Fellow in the field of polymers at the Weizmann Institute in </span><st1:country-region><st1:place><span
  style='font-size:12.0pt;font-family:"Times New Roman"'>Israel</span></st1:place></st1:country-region><span
style='font-size:12.0pt;font-family:"Times New Roman"'>.<span
style='mso-spacerun:yes'>  </span>Professor Borejdo has served as a Research
Biophysicist at the </span><st1:place><st1:PlaceType><span style='font-size:
  12.0pt;font-family:"Times New Roman"'>University</span></st1:PlaceType><span
 style='font-size:12.0pt;font-family:"Times New Roman"'> of </span><st1:PlaceName><span
  style='font-size:12.0pt;font-family:"Times New Roman"'>California</span></st1:PlaceName></st1:place><span
style='font-size:12.0pt;font-family:"Times New Roman"'>, </span><st1:City><st1:place><span
  style='font-size:12.0pt;font-family:"Times New Roman"'>San Francisco</span></st1:place></st1:City><span
style='font-size:12.0pt;font-family:"Times New Roman"'> and the Baylor Research
Institute in </span><st1:place><st1:City><span style='font-size:12.0pt;
  font-family:"Times New Roman"'>Dallas</span></st1:City><span
 style='font-size:12.0pt;font-family:"Times New Roman"'>, </span><st1:State><span
  style='font-size:12.0pt;font-family:"Times New Roman"'>Texas</span></st1:State></st1:place><span
style='font-size:12.0pt;font-family:"Times New Roman"'>.<span
style='mso-spacerun:yes'>  </span>Currently, he is a Professor of Molecular
Biology at the University of North Texas Health Science Center in </span><st1:place><st1:City><span
  style='font-size:12.0pt;font-family:"Times New Roman"'>Fort Worth</span></st1:City><span
 style='font-size:12.0pt;font-family:"Times New Roman"'>, </span><st1:State><span
  style='font-size:12.0pt;font-family:"Times New Roman"'>Texas</span></st1:State></st1:place><span
style='font-size:12.0pt;font-family:"Times New Roman"'>.<span
style='mso-spacerun:yes'>  </span>Professor Borejdo has authored or co-authored
76 refereed journal publications and is an active member of the American
Biophysical Society and American Microscopical Society.<o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><o:p>&nbsp;</o:p></p>

<p class=MsoNormal><o:p>&nbsp;</o:p></p>

<p class=MsoNormal align=center style='text-align:center'>**********************************************************************</p>

<h1 align=left style='text-align:left'><st1:time Minute="30" Hour="13">1:30 –
 2:15</st1:time></h1>

<p class=MsoTitle><span style='mso-bidi-font-weight:bold'>Holographic
Visualization of 3D Data for Medical Applications<o:p></o:p></span></p>

<p class=MsoNormal align=center style='text-align:center'>Harold R. “Skip” Garner,
Jr., Ph.D.,</p>

<p class=MsoNormal align=center style='text-align:center'>Bala Munjuluri, and
Michael L. Huebschman</p>

<p class=MsoNormal align=center style='text-align:center'>UT Southwestern <st1:place><st1:PlaceName>Medical</st1:PlaceName>
 <st1:PlaceType>Center</st1:PlaceType></st1:place></p>

<p class=MsoNormal align=center style='text-align:center'><st1:Street><st1:address>5323
  Harry Hines Blvd.</st1:address></st1:Street></p>

<p class=MsoNormal align=center style='text-align:center'><st1:place><st1:City>Dallas</st1:City>,
 <st1:State>TX</st1:State> <st1:PostalCode>75390-8591</st1:PostalCode></st1:place></p>

<p class=MsoNormal style='text-align:justify'><o:p>&nbsp;</o:p></p>

<p class=MsoNormal style='text-align:justify'><b style='mso-bidi-font-weight:
normal'><u>ABSTRACT</u></b>:<span style='mso-spacerun:yes'>  </span>The display
of dynamic color holographic images is possible by computing the hologram of
objects in a three-dimensional scene and then transcribing the two-dimensional
digital hologram onto a digital micromirror system illuminated with coherent
light.<span style='mso-spacerun:yes'>  </span>Two proof-of-principle
instruments have been developed which, respectively, reconstruct real and virtual
images.<span style='mso-spacerun:yes'>  </span>This new, truly holographic 3-D
viewing system has a broad range of applications, including heads-up displays,
video games, television and workstations for medical applications – sonograms,
MRI, etc.<span style='mso-spacerun:yes'>  </span>This system can display any
3-D data, real or computationally synthesized, and can update the hologram of
moving objects in near-real time using new algorithms developed especially for
the display.<span style='mso-spacerun:yes'>   </span>The underlying process,
its characteristics, limitations and utility will be discussed.<span
style='mso-spacerun:yes'>  </span>This technology forms the basis for a
potential new company, with the working name, Holomedix, that is focused on the
medical display applications market.<span style='mso-spacerun:yes'>  </span><span
style='font-family:Times;mso-bidi-font-family:"Times New Roman"'>Additional
information can be found on the www at <span class=MsoHyperlink><a
href="http://innovation.swmed.edu/">http://innovation.swmed.edu</a></span> and
in the following references: <o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span style='font-family:Times;
mso-bidi-font-family:"Times New Roman"'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='margin-left:.75in;text-align:justify;text-indent:
-.5in;mso-list:l0 level1 lfo1;tab-stops:list .75in'><![if !supportLists]><span
style='mso-list:Ignore'>1.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><![endif]>Bala Munjuluri, Michael L. Huebschman, and<span
style='mso-spacerun:yes'>  </span>Harold R. Garner, Rapid Hologram Updates for
Real Time Volumetric Information Display, in press, Applied Optics</p>

<p class=MsoBodyText style='margin-left:.75in;text-align:justify;text-indent:
-.5in;mso-list:l0 level1 lfo1;tab-stops:list .75in'><![if !supportLists]><span
style='font-size:12.0pt;mso-bidi-font-size:10.0pt;font-family:"Times New Roman";
mso-fareast-font-family:"Times New Roman"'><span style='mso-list:Ignore'>2.<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span style='font-size:12.0pt;mso-bidi-font-size:
10.0pt;font-family:"Times New Roman"'>Michael L. Huebschman,<span
style='mso-spacerun:yes'>  </span>Bala Munjuluria,<span
style='mso-spacerun:yes'>  </span>Jeremy Hunt, Harold R. Garner, Holographic
video display using digital micromirrors, in press, SPIE<o:p></o:p></span></p>

<p class=MsoBodyText style='margin-left:.75in;text-align:justify;text-indent:
-.5in;mso-list:l0 level1 lfo1;tab-stops:list .75in'><![if !supportLists]><span
style='font-size:12.0pt;mso-bidi-font-size:10.0pt;font-family:"Times New Roman";
mso-fareast-font-family:"Times New Roman"'><span style='mso-list:Ignore'>3.<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span style='font-size:12.0pt;mso-bidi-font-size:
10.0pt;font-family:"Times New Roman"'>Michael L. Huebschman, Bala Munjuluri and
Harold R. Garner, Dynamic Holographic 3-D Image Projection, Optics Express,
Vol. 11, No. 5, 437-445, March 2003.<o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><o:p>&nbsp;</o:p></p>

<p class=MsoNormal style='text-align:justify'><b style='mso-bidi-font-weight:
normal'><u>BIOGRAPHY</u></b>:<span style='mso-spacerun:yes'>  </span><span
style='font-family:Times;mso-bidi-font-family:"Times New Roman"'>Skip received
his BS in Nuclear Engineering at the </span><st1:place><st1:PlaceType><span
  style='font-family:Times;mso-bidi-font-family:"Times New Roman"'>University</span></st1:PlaceType><span
 style='font-family:Times;mso-bidi-font-family:"Times New Roman"'> of </span><st1:PlaceName><span
  style='font-family:Times;mso-bidi-font-family:"Times New Roman"'>Missouri</span></st1:PlaceName></st1:place><span
style='font-family:Times;mso-bidi-font-family:"Times New Roman"'> - Rolla in
1976.<span style='mso-spacerun:yes'>  </span>Skip received a Ph.D. in
plasma/high temperature matter physics from the </span><st1:place><st1:PlaceType><span
  style='font-family:Times;mso-bidi-font-family:"Times New Roman"'>University</span></st1:PlaceType><span
 style='font-family:Times;mso-bidi-font-family:"Times New Roman"'> of </span><st1:PlaceName><span
  style='font-family:Times;mso-bidi-font-family:"Times New Roman"'>Wisconsin</span></st1:PlaceName></st1:place><span
style='font-family:Times;mso-bidi-font-family:"Times New Roman"'>, </span><st1:City><st1:place><span
  style='font-family:Times;mso-bidi-font-family:"Times New Roman"'>Madison</span></st1:place></st1:City><span
style='font-family:Times;mso-bidi-font-family:"Times New Roman"'> in 1982.<span
style='mso-spacerun:yes'>  </span>He also holds an honorary professional
engineering degree.<span style='mso-spacerun:yes'>  </span><o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify;text-indent:.5in'><span
style='font-family:Times;mso-bidi-font-family:"Times New Roman"'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span style='font-family:Times;
mso-bidi-font-family:"Times New Roman"'>Skip worked for 12 years at General
Atomics in </span><st1:place><st1:City><span style='font-family:Times;
  mso-bidi-font-family:"Times New Roman"'>La Jolla</span></st1:City><span
 style='font-family:Times;mso-bidi-font-family:"Times New Roman"'>, </span><st1:State><span
  style='font-family:Times;mso-bidi-font-family:"Times New Roman"'>California</span></st1:State></st1:place><span
style='font-family:Times;mso-bidi-font-family:"Times New Roman"'>, where he
conducted experimental and theoretical research for the Department of Energy at
international fusion research facilities, principally in </span><st1:country-region><st1:place><span
  style='font-family:Times;mso-bidi-font-family:"Times New Roman"'>Japan</span></st1:place></st1:country-region><span
style='font-family:Times;mso-bidi-font-family:"Times New Roman"'> (5 years) and
the </span><st1:place><span style='font-family:Times;mso-bidi-font-family:"Times New Roman"'>Soviet
 Union</span></st1:place><span style='font-family:Times;mso-bidi-font-family:
"Times New Roman"'>.<span style='mso-spacerun:yes'>   </span>In the last 6
years at General Atomics, he was a founding member of The Institute for
Development and Application of Advanced Technologies.<span
style='mso-spacerun:yes'>  </span><o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify;text-indent:.5in'><o:p>&nbsp;</o:p></p>

<p class=MsoBodyText style='text-align:justify'><span style='font-size:12.0pt;
font-family:"Times New Roman"'>Skip currently holds the P. O’B. Montgomery,
M.D., Distinguished Chair, is a Professor of Biochemistry and Internal
Medicine, at UT Southwestern Medical Center.<span style='mso-spacerun:yes'>   
</span>He sits on numerous corporate advisory boards, advises for numerous
governmental agencies and has 15 issued patents.<span
style='mso-spacerun:yes'>  </span><o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><o:p>&nbsp;</o:p></p>

<p class=MsoNormal style='text-align:justify'><o:p>&nbsp;</o:p></p>

<p class=MsoNormal align=center style='text-align:center'>**********************************************************************</p>

<h1 align=left style='text-align:left'><st1:time Minute="25" Hour="14">2:25 –
 3:10</st1:time></h1>

<p class=MsoTitle><span style='mso-bidi-font-weight:bold'>Tag-free </span>B<span
style='mso-bidi-font-weight:bold'>iosensors with </span>R<span
style='mso-bidi-font-weight:bold'>esonant </span>P<span style='mso-bidi-font-weight:
bold'>hotonic </span>L<span style='mso-bidi-font-weight:bold'>attices<o:p></o:p></span></p>

<p class=MsoNormal align=center style='text-align:center'><span
style='color:black'>Debra Wawro, P.S. Priambodo, and Robert Magnusson<o:p></o:p></span></p>

<p class=MsoNormal align=center style='text-align:center'><span
style='color:black'>Resonant Sensors Incorporated<o:p></o:p></span></p>

<p class=MsoNormal align=center style='text-align:center'><st1:Street><st1:address><span
  style='color:black'>202 E. Border St., #201</span></st1:address></st1:Street><span
style='color:black'><o:p></o:p></span></p>

<p class=MsoNormal align=center style='text-align:center'><st1:place><st1:City><span
  style='color:black'>Arlington</span></st1:City><span style='color:black'>, </span><st1:State><span
  style='color:black'>TX</span></st1:State><span style='color:black'> </span><st1:PostalCode><span
  style='color:black'>76010</span></st1:PostalCode></st1:place><span
style='color:black'><o:p></o:p></span></p>

<p class=MsoNormal><span style='color:black'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify'><b style='mso-bidi-font-weight:
normal'><u>ABSTRACT</u></b>:<span style='mso-spacerun:yes'>  </span>A new
photonic sensor concept is presented for detection of biological and chemical
agents.<span style='mso-spacerun:yes'>  </span><span style='color:black'>The
heart of the sensor is a periodic dielectric waveguide in which resonant leaky
modes are excited by an incident optical wave.<span style='mso-spacerun:yes'> 
</span>Biochemical reactions occurring at the sensor’s surface cause changes in
the reflection spectra (amplitude and phase) that are measured to identify the
binding event without chemical tags.<span style='mso-spacerun:yes'>  </span></span>Numerous
computed examples and experimental results illustrate key sensor properties and
define promising paths for establishing useful sensor technology based on these
ideas<span style='color:black'>.<span style='mso-spacerun:yes'>  </span>T</span>he
technology has broad applicability including homeland security, environmental
and industrial monitoring and pharmaceutical drug development.</p>

<p class=MsoNormal style='text-align:justify'><span style='color:black'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify'><b style='mso-bidi-font-weight:
normal'><u><span style='color:black'>BIOGRAPHY</span></u></b><span
style='color:black'>:<span style='mso-spacerun:yes'>  </span></span>Debra Wawro
is founder and CEO of Resonant Sensors Incorporated, a newly formed optical
sensor company from the Arlington Technology Incubator at the <st1:place><st1:PlaceType>University</st1:PlaceType>
 of <st1:PlaceName>Texas</st1:PlaceName></st1:place> at <st1:City><st1:place>Arlington</st1:place></st1:City>.<span
style='mso-spacerun:yes'>  </span>Resonant Sensors Inc. is developing novel
bio- and chemical sensors for Homeland Security applications based on
guided-mode resonance technology.<span style='mso-spacerun:yes'>  
</span>Debra’s background and education is in photonics, with a particular
emphasis on diffractive optics and sensors.<span style='mso-spacerun:yes'> 
</span>She has worked in Telecom for several years at Marconi Communications
and later Tellabs as a manager and staff engineer.<span
style='mso-spacerun:yes'>  </span>She has also worked in a faculty position at
the University of Texas Southwest Medical Center at <st1:City><st1:place>Dallas</st1:place></st1:City>
researching optically activated drug delivery methods.<span
style='mso-spacerun:yes'>  </span>She obtained her MSEE and BSEE from the <st1:place><st1:PlaceType>University</st1:PlaceType>
 of <st1:PlaceName>Texas</st1:PlaceName></st1:place> at <st1:City><st1:place>Arlington</st1:place></st1:City>
in 1999 and 1997 respectively.<span style='mso-spacerun:yes'>  </span>She has four
pending patents related to guided-mode resonance sensors and other optical
components for telecom, and is a member of OSA, IEEE and SPIE.<span
style='mso-spacerun:yes'>    </span><span style='color:black'><o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span style='color:black'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal align=center style='text-align:center'>**********************************************************************</p>

<h1 align=left style='text-align:left'><st1:time Minute="30" Hour="15">3:30 –
 4:05</st1:time></h1>

<p class=MsoTitle>Exploring Microgravity Bioreactors for Pancreatic Islet Cell
Transplantation</p>

<p class=MsoNormal align=center style='text-align:center'><span
style='mso-bidi-font-size:14.0pt'>Lynne P. Rutzky, Ph.D.<o:p></o:p></span></p>

<p class=MsoNormal align=center style='text-align:center'><span
style='mso-bidi-font-size:14.0pt'>Associate Professor of Surgery<o:p></o:p></span></p>

<p class=MsoNormal align=center style='text-align:center'><span
style='mso-bidi-font-size:14.0pt'>Division of Immunology and Organ
Transplantation<o:p></o:p></span></p>

<p class=MsoNormal align=center style='text-align:center'><span
style='mso-bidi-font-size:14.0pt'>University of </span><st1:place><st1:PlaceName><span
  style='mso-bidi-font-size:14.0pt'>Texas</span></st1:PlaceName><span
 style='mso-bidi-font-size:14.0pt'> </span><st1:PlaceName><span
  style='mso-bidi-font-size:14.0pt'>Health</span></st1:PlaceName><span
 style='mso-bidi-font-size:14.0pt'> </span><st1:PlaceName><span
  style='mso-bidi-font-size:14.0pt'>Science</span></st1:PlaceName><span
 style='mso-bidi-font-size:14.0pt'> </span><st1:PlaceType><span
  style='mso-bidi-font-size:14.0pt'>Center</span></st1:PlaceType></st1:place><span
style='mso-bidi-font-size:14.0pt'> at </span><st1:City><st1:place><span
  style='mso-bidi-font-size:14.0pt'>Houston</span></st1:place></st1:City><span
style='mso-bidi-font-size:14.0pt'><o:p></o:p></span></p>

<p class=MsoNormal align=center style='text-align:center'><st1:place><st1:City><span
  style='mso-bidi-font-size:14.0pt'>Houston</span></st1:City><span
 style='mso-bidi-font-size:14.0pt'>, </span><st1:State><span style='mso-bidi-font-size:
  14.0pt'>Texas</span></st1:State><span style='mso-bidi-font-size:14.0pt'><span
 style='mso-spacerun:yes'>  </span></span><st1:PostalCode><span
  style='mso-bidi-font-size:14.0pt'>77030</span></st1:PostalCode></st1:place><span
style='mso-bidi-font-size:14.0pt'><o:p></o:p></span></p>

<address><span style='mso-bidi-font-size:12.0pt'><o:p>&nbsp;</o:p></span></address>

<p class=MsoBodyText style='text-align:justify'><b style='mso-bidi-font-weight:
normal'><u><span style='font-size:12.0pt;mso-bidi-font-size:10.0pt;font-family:
"Times New Roman"'>ABTSRACT</span></u></b><span style='font-size:12.0pt;
mso-bidi-font-size:10.0pt;font-family:"Times New Roman"'>:<span
style='mso-spacerun:yes'>  </span>Type I insulin dependent diabetes mellitus
remains a major cause of morbidity and mortality and therapy with exogenous
insulin only delays onset and severity of end organ complications, such as
kidney disease and vascular and peripheral nerve damage. While whole organ pancreas
transplant is a serious surgical risk, islet cell transplantation is cost
effective and less invasive procedure, which may help prevent future disease
complications. Recently, Shapiro’s (2000) steroid-free </span><st1:place><st1:City><span
  style='font-size:12.0pt;mso-bidi-font-size:10.0pt;font-family:"Times New Roman"'>Edmonton</span></st1:City></st1:place><span
style='font-size:12.0pt;mso-bidi-font-size:10.0pt;font-family:"Times New Roman"'>
immunosuppressive protocol stimulated renewed interest in islet cell
transplantation. Human islets for transplantation remain a scarce tissue
resource due to a limited source of donor organs and islet cell losses during
isolation and culture. The hypothesis for our work is that bioreactor-culture
of islets in RWV bioreactors:<span style='mso-spacerun:yes'>  </span>1)
preserves islet morphology and function and 2) produces large, sinusoidal
channels only within bioreactor-cultured islets, improving islet nutrition and
reducing apoptosis. The rotating wall vessel bioreactor or Rotary Cell Culture
System (RCCS, Synthecon, Inc., Houston, TX), possesses some aspects of
microgravity and<span style='mso-spacerun:yes'>  </span>is characterized by
continuous free fall of cells through the culture medium at terminal settling
velocities, randomized gravitational vectors, low shear stress, and excellent
mass transfer of nutrients. Cells cultured in this system tend to cluster
together and the low shear micro-environment surrounding the cells may
concentrate various growth factors. Our work shows clearly in a mouse allograft
model that islets cultured in RWV bioreactors have reduced immunogenicity and
can produce long-term allograft survival without immunosuppression. Moreover,
both human and mouse bioreactor-cultured islets have well-preserved
ultrastructural morphology and high levels of the hormones insulin, glucagon,
and somatostatin. These cultured islets have less apoptosis as evaluated by
TUNEL staining, TUNEL electron microscopy and caspase activity. Both closed
chamber-cultured and perfusion bioreactor-cultured islets develop intercellular
channels only during bioreactor culture when compared to stationary dish
culture and freshly isolated islets, which facilitates entrance of nutrients
into the islet interior, promoting development of physiologically superior
islets, which may help overcome the critical shortage of islets for clinical
transplantation.<o:p></o:p></span></p>

<p class=MsoBodyText style='text-align:justify'><span style='font-size:11.0pt;
mso-bidi-font-size:12.0pt;font-family:"Times New Roman"'><o:p>&nbsp;</o:p></span></p>

<p class=MsoBodyText style='text-align:justify'><b style='mso-bidi-font-weight:
normal'><u><span style='font-size:12.0pt;font-family:"Times New Roman"'>BIOGRAPHY</span></u></b><span
style='font-size:12.0pt;font-family:"Times New Roman"'>:<span
style='mso-spacerun:yes'>  </span>Lynne P. Rutzky, Ph.D. is Associate Professor
of Surgery at The University of Texas Health Science Center-Houston Medical
School, Department of Surgery, Division of Immunology and Organ
Transplantation. Dr. Rutzky received a B.S. degree from The University of
Wisconsin-Madison and M.S. and Ph.D. degrees in Medical Microbiology from the </span><st1:place><st1:PlaceType><span
  style='font-size:12.0pt;font-family:"Times New Roman"'>University</span></st1:PlaceType><span
 style='font-size:12.0pt;font-family:"Times New Roman"'> of </span><st1:PlaceName><span
  style='font-size:12.0pt;font-family:"Times New Roman"'>Illinois Medical
  Center-Chicago</span></st1:PlaceName></st1:place><span style='font-size:12.0pt;
font-family:"Times New Roman"'> and a Master of Public Health Degree in
Occupational Health and Safety from The University of Texas Health Science
Center-Houston School of Public Health. Dr. Rutzky chairs The University of
Texas Health Science Center-Houston Institutional Biosafety Committee. She is
interested in developing and characterizing various cell culture model systems,
including three dimensional cultures of human colorectal cancer cells in hollow
fiber culture and more recently the culture of pancreatic islets for
transplantation in microgravity-simulating rotating wall vessel bioreactors. <span
style='mso-spacerun:yes'> </span><o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><o:p>&nbsp;</o:p></p>

<p class=MsoNormal style='text-align:justify'><o:p>&nbsp;</o:p></p>

<p class=MsoNormal align=center style='text-align:center'>**********************************************************************</p>

<h1 align=left style='text-align:left'>4:15 – 5:00</h1>

<h3><span style='mso-spacerun:yes'> </span>“Clinical Applications of
Photochemical Bonding”</h3>

<p class=MsoNormal align=center style='text-align:center'>J. Lester Matthews,
Ph.D.</p>

<p class=MsoNormal align=center style='margin-left:.25in;text-align:center'>President</p>

<p class=MsoNormal align=center style='margin-left:.25in;text-align:center'>MicroBioMed
Corporation</p>

<p class=MsoNormal align=center style='margin-left:.25in;text-align:center'><st1:Street><st1:address>2454
  Walnut Ridge Street</st1:address></st1:Street></p>

<p class=MsoNormal align=center style='margin-left:.25in;text-align:center'><st1:place><st1:City>Dallas</st1:City>,
 <st1:State>TX</st1:State><span style='mso-spacerun:yes'>  </span><st1:PostalCode>75229</st1:PostalCode></st1:place></p>

<p class=MsoNormal align=center style='text-align:center'><o:p>&nbsp;</o:p></p>

<p class=MsoNormal style='text-align:justify'><b style='mso-bidi-font-weight:
normal'><u>ABSTRACT</u></b>:<span style='mso-spacerun:yes'>  </span>Several
photochemicals have been evaluated for potential use in bonding and/or
cross-linking of animal structural proteins to achieve tissue repair; for
fabrication of tissue prostheses; or for anchoring of chemicals for control delivery
at select tissue sites. A major criterion in our selection was the excitation
wavelength of light required to activate the bonding process. Several UV
excited photochemicals show bonding properties but we elected to use visible
light excited species in order to minimize the effect of direct irradiation of
tissue with UV.<span style='mso-spacerun:yes'>  </span>The class of
photochemicals selected for complete evaluation are aqueous based
naphthalimides that exhibit low tissue toxicity and are excited by light in the
blue visible range. Naphthalimides can also be attached to other chemicals
using dark chemistry preserving the light response property of the
naphthalimide for subsequent use in tissue bonding. Naphthalimides can be used
in conjunction with various filler materials to improve adhesive properties
with uneven surfaces, tissue defects, and to improve the gap spanning potential
with minimal applied compression.<span style='mso-spacerun:yes'>  </span>The
addition of fillers either attached to naphthalimide or free in suspension with
naphthalimide have demonstrated greater efficiency in tissue bonding in either
a tissue overlapped or tissue abutted mode. Filler material may include
polysaccharides (i.e. chitosan, etc.), proteins (i.e. collagen,
fibrin/thrombin,etc.), or potentially other synthetic or biomaterials. Several
advantages to using chitosan-based naphthalamide formulations have been
demonstrated.<span style='mso-spacerun:yes'>  </span>First, overall tissue bond
strengths have been improved, both in a collagenous pericardial model as well
as in the adherence of a pericardial patch to the adventitial layer of a torn
arterial wall. Light exposure of the chitosan-bradsyl-naphthalimide prior to
application of the formulation to tissue has yielded bond strengths of 518 <sub><!--[if gte vml 1]><v:shapetype
 id="_x0000_t75" coordsize="21600,21600" o:spt="75" o:preferrelative="t"
 path="m@4@5l@4@11@9@11@9@5xe" filled="f" stroked="f">
 <v:stroke joinstyle="miter"/>
 <v:formulas>
  <v:f eqn="if lineDrawn pixelLineWidth 0"/>
  <v:f eqn="sum @0 1 0"/>
  <v:f eqn="sum 0 0 @1"/>
  <v:f eqn="prod @2 1 2"/>
  <v:f eqn="prod @3 21600 pixelWidth"/>
  <v:f eqn="prod @3 21600 pixelHeight"/>
  <v:f eqn="sum @0 0 1"/>
  <v:f eqn="prod @6 1 2"/>
  <v:f eqn="prod @7 21600 pixelWidth"/>
  <v:f eqn="sum @8 21600 0"/>
  <v:f eqn="prod @7 21600 pixelHeight"/>
  <v:f eqn="sum @10 21600 0"/>
 </v:formulas>
 <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
 <o:lock v:ext="edit" aspectratio="t"/>
</v:shapetype><v:shape id="_x0000_i1025" type="#_x0000_t75" style='width:9.75pt;
 height:11.25pt' o:ole="">
 <v:imagedata src="BIOTECH_ABSTRACTS_AND_BIOS_COMBINED_files/image001.wmz"
  o:title=""/>
</v:shape><![endif]--><![if !vml]><img border=0 width=13 height=15
src="BIOTECH_ABSTRACTS_AND_BIOS_COMBINED_files/image003.gif" v:shapes="_x0000_i1025"><![endif]></sub><!--[if gte mso 9]><xml>
 <o:OLEObject Type="Embed" ProgID="Equation.3" ShapeID="_x0000_i1025"
  DrawAspect="Content" ObjectID="_1183399297">
 </o:OLEObject>
</xml><![endif]--><span style='mso-spacerun:yes'> </span>160 g/cm<sup>2</sup>
enabling significant tissue bonding without requiring direct trans-illumination
of the tissue. Second, hemostasis is readily achieved.<span
style='mso-spacerun:yes'>  </span>Alternatively, naphthalimide derivatives in
the dimer form demonstrate bond strengths of 1.8 kg/cm<sup>2</sup> when
irradiated within the tissue. Cell culture data demonstrates that the chitosan-based
naphthalimide adhesive has an excellent biocompatibility profile and short term
studies in tissues show little or no inflammation. Long term studies of the
naphthalimide dimers in repaired sheep meniscus show no pathologic tissue
response or toxicity for two years duration, all treated animals functioning
normally following repair. </p>

<p class=MsoNormal style='text-align:justify'><o:p>&nbsp;</o:p></p>

<p class=MsoNormal style='text-align:justify'>Our naphthalimide formulations
have now been tested in a variety of tissues and potential clinical
applications including: repair of torn meniscal tissue in the knee,
stabilization of injected particles of collagen to treat incontinence, bonding
of torn dura, delivery of drugs in local tissue sites such as anti-restenotic
agents to coronary artery tissues, repair of corneal tear, bonding of synthetic
materials such as nylon sheets to tissue, fabrication of artificial vessels
using collagen sheets, anchoring of sunscreen materials to outer skin cells,
repair of rabbit aorta capable of withstanding 1,200mm Hg perfusion pressure.
The formulations work well with natural and synthetic films of collagen
composition providing a means of obtaining marginal seals and elimination of
the need for sutures. We are presently focused on two applications for ultimate
evaluation by regulatory agencies of this new device formulation and seek
partners for other activity.<span style='mso-spacerun:yes'>     </span></p>

<p class=MsoNormal><o:p>&nbsp;</o:p></p>

<p class=MsoNormal style='text-align:justify'><b style='mso-bidi-font-weight:
normal'><u>BIOGRAPHY</u></b>:<span style='mso-spacerun:yes'>  </span>Dr.
Matthews completed his B.S. and M.S. degrees in Biology at the <st1:PlaceType>University</st1:PlaceType>
of <st1:PlaceName>North Texas</st1:PlaceName> and his Ph.D. in Physiology at
the <st1:place><st1:PlaceType>University</st1:PlaceType> of <st1:PlaceName>Illinois</st1:PlaceName></st1:place>.
He served in the Navy from 1944 to 1946. He held teaching positions in <st1:PlaceName>Cisco</st1:PlaceName>
<st1:PlaceType>Junior College</st1:PlaceType>, <st1:City>University of North</st1:City>
<st1:State>Texas</st1:State>, <st1:PlaceType>University</st1:PlaceType> of <st1:PlaceName>Illinois</st1:PlaceName>,
Baylor College of Dentistry, and <st1:place><st1:PlaceName>Baylor</st1:PlaceName>
 <st1:PlaceType>University</st1:PlaceType></st1:place>. He served on the
graduate faculty of <st1:place><st1:PlaceName>Baylor</st1:PlaceName> <st1:PlaceType>University</st1:PlaceType></st1:place>,
University of Texas Southwestern Medical School, and as Adjunct Professor at
Southern Methodist University. He was Associate Dean of continuing education at
<st1:place><st1:PlaceName>Baylor</st1:PlaceName> <st1:PlaceName>Medical</st1:PlaceName>
 <st1:PlaceType>Center</st1:PlaceType></st1:place>. He subsequently served as
the Executive Director of Baylor Research Institute of Baylor Medical Center
for eight years before retiring from Baylor. He had research fellowships from
the Nuffield trust of <st1:PlaceName>Oxford</st1:PlaceName> <st1:PlaceType>University</st1:PlaceType>
and a research fellowship from the Hospital for Children in <st1:place><st1:City>Paris</st1:City></st1:place>.
He served on grant review committees for NIH, NASA, American Institute for
Biology, Army Ballistic Command and Kroc Foundation.<span
style='mso-spacerun:yes'>  </span>He served on the Editorial Board of six
journals, published numerous papers, and holds sixteen patents.<span
style='mso-spacerun:yes'>  </span>He is currently President of PhotoBioMed
Corporation of <st1:place><st1:City>Dallas</st1:City></st1:place>.<span
style='mso-spacerun:yes'>  </span></p>

</div>

</body>

</html>
